Company Encyclopedia
View More
name
GZYK
002524.SZ
Guangzheng Eye Hospital Group Co., Ltd. provides various ophthalmic medical services in China. It operates through Steel Structure, Energy, and Medical and Health Sector segments. The company offers diagnosis and treatment of various eye diseases; medical optometry services; invests in, operates, and manages eye hospitals; and provides related services.
175.65 B
002524.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
Health Care FacilitiesIndustry
Industry Ranking9/9
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-77.83%E
    • Profit Margin-17.92%D
    • Gross Margin34.49%C
  • Growth ScoreE
    • Revenue YoY-9.43%D
    • Net Profit YoY-598.84%E
    • Total Assets YoY-15.15%E
    • Net Assets YoY-54.16%E
  • Cash ScoreE
    • Cash Flow Margin-558.04%E
    • OCF YoY-9.43%D
  • Operating ScoreB
    • Turnover0.65B
  • Debt ScoreE
    • Gearing Ratio89.56%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Zhitong A-share lock-up release overview | October 27

    On October 27th, a total of 10 listed companies had their restricted shares unlocked, with a total market value of approximately 18.54 billion yuan. The specific situation of the restricted shares unlocked today is as follows: Stock Abbreviation Stock Code Restricted Share Type Unlocked Shares Xiamen Bank 601187 Extended Restricted Lock-up Period Circulation 1.348 billion GZYK 002524 Equity Incentive Restricted Circulation 2.2245 million SPAS 603168 Equity Incentive Restricted Circulation 30,000 Yifeng Pharmacy 603939 Equity Incentive Restricted Circulation 195,000 Jihong Co., Ltd. 002803 Equity Incentive Restricted Circulation 1.98 million Mingyang Circuit 300739 Equity Incentive Restricted Circulation 1.2387 million Arrow Home 001322 Pre-issue Shares Restricted Circulation 800 million Ruichen Environmental Protection 301273 Pre-issue Shares Restricted Circulation 37.0125 million Jinchengzi 688291 6.9 million Wei Ce Technology 688372 270.328 million

    Zhitong·
    SH
    601187
    -0.96%
    SZ
    002524
    +0.22%
    SH
    603939
    -0.09%
    Zhitong·
    SH
    601187
    -0.96%
    SZ
    002524
    +0.22%
    SH
    603939
    -0.09%

    GZYK released its performance for the first three quarters, with a net profit attributable to the parent company of 173,400 yuan, a year-on-year increase of 100.83%

    According to the Zhitong Finance APP, GZYK released its third-quarter report for 2025. In the first three quarters, the company achieved an operating income of 663 million yuan, a year-on-year decrease of 5.05%. The net profit attributable to shareholders of the listed company was 173,400 yuan, a year-on-year increase of 100.83%. The net loss attributable to shareholders of the listed company, after deducting non-recurring gains and losses, was 9.1753 million yuan

    Zhitong·
    SZ
    002524
    +0.22%
    Zhitong·
    SZ
    002524
    +0.22%

    GZYK: Net profit loss of RMB 1.2455 million in the third quarter, a decrease of 94.36%

    GZYK announced that the revenue for the third quarter was 227 million yuan, an increase of 4.82% year-on-year; the net profit loss was 1.2455 million yuan, a decrease of 94.36%. The revenue for the first three quarters was 663 million yuan, a year-on-year decrease of 5.05%; the net profit was 173,400 yuan, an increase of 100.83% year-on-year

    Zhitong·
    SZ
    002524
    +0.22%
    Zhitong·
    SZ
    002524
    +0.22%

    GZYK's subsidiary applies for credit, with the cumulative guarantee amount accounting for 453.50% of net assets

    GZYK announced that its wholly-owned subsidiary Zhongxing Ophthalmology and New Vision Ophthalmology applied for a credit limit of 30 million yuan from the Shanghai Branch of China Merchants Bank, with the company and related parties providing joint liability guarantees. After this guarantee, the total guarantee amount for the company and its subsidiaries reaches 511.09 million yuan, accounting for 453.50% of the most recent audited net assets. This guarantee is an internal mutual guarantee, with no external guarantee risk

    Zhitong·
    SZ
    002524
    +0.22%
    Zhitong·
    SZ
    002524
    +0.22%

    Ophthalmology medical concept stocks surged, SPAS hit the daily limit in the afternoon

    Ophthalmology medical concept stocks surged during the session, with SPAS hitting the daily limit, Xingqi Eye Medicine rising over 10%, Lifeon Pharmaceutical previously hitting the daily limit, and Bio-S, Eyebright Medical, GZYK, and HESH also following suit

    Zhitong·
    SZ
    003020
    -0.65%
    SZ
    301096
    +2.48%
    SH
    688050
    -0.16%
    Zhitong·
    SZ
    003020
    -0.65%
    SZ
    301096
    +2.48%
    SH
    688050
    -0.16%
    © 2025 Longbridge｜Disclaimer